Evidence map›Paper›PMID 33083913›Full record

Trial reportInternational journal of clinical oncology2021

Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.

Yoichiro Yoshida, Takeshi Yamada, Hirohiko Kamiyama, Chihiro Kosugi, Keiichiro Ishibashi, Hiroshi Yoshida, Hideyuki Ishida, Satoru Yamaguchi, Hidekazu Kuramochi, Atsuko Fukazawa and 8 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Yoichiro YoshidaDepartment of Gastroenterological Surgery, Faculty of Medicine, Fukuoka University, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. yyoshida@fukuoka-u.ac.jp.ORCID http://orcid.org/0000-0001-6583-7352
Takeshi YamadaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Hirohiko KamiyamaDepartment of Coloproctological Surgery, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Chihiro KosugiDepartment of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
Keiichiro IshibashiDepartment of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Hiroshi YoshidaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Hideyuki IshidaDepartment of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Satoru YamaguchiDepartment of Surgical Oncology, Dokkyo Medical University, Tochigi, Japan.
Hidekazu KuramochiDepartment of Chemotherapy, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.
Atsuko FukazawaDepartment of Gastroenterological Surgery, Iwata City Hospital, Shizuoka, Japan.
Hiromichi SonodaDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Kazuhiko YoshimatsuDepartment of Surgery, Saiseikai Kurihashi Hospital, Saitama, Japan.
Akihisa MatsudaDepartment of Surgery, Nippon Medical School Chiba Hokuso Hospital, Chiba, Japan.
Suguru HasegawaDepartment of Gastroenterological Surgery, Faculty of Medicine, Fukuoka University, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Kazuhiro SakamotoDepartment of Coloproctological Surgery, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Toshiaki OtsukaDept of Hygiene and Public Health, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Keiji KodaDepartment of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
TAS CC3 Study Group.
Nippon Medical School · JPFukuoka University · JPJuntendo University · JPSocial Insurance Saitama Chuo Hospital · JPTeikyo University Chiba Medical Center · JPChiba Hokusou Hospital · JPDokkyo Medical University · JPIwata City Hospital · JPSaiseikai Ibaraki Hospital · JPShiga University of Medical Science · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTAS-102 improved the overall survival of metastatic colorectal cancer (CRC) patients with a median progression-free survival (PFS) in the RECOURSE trial. Subsequently, the combination of TAS-102 and bevacizumab was shown to extend the median PFS (C-TASK FORCE study). However, the study included patients who received second- and third-line treatment. Our study exclusively examined patients receiving this combination as a third-line treatment to investigate the clinical impact beyond cytotoxic doublets.

methodsThis investigator-initiated, open-label, single-arm, multi-centered phase II study was conducted in Japan. Eligible CRC patients were refractory or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin in first- and second-line therapy. TAS-102 (35 mg/m

resultsBetween June 2016 and August 2017, 32 patients were enrolled. All patients previously received bevacizumab. The median PFS was 4.5 months; the median overall survival was 9.3 months. Partial response was observed in two patients. The most common adverse events above grade 3 were neutropenia followed by thrombocytopenia. There were no non-hematological adverse events above grade 3 and no treatment-related deaths occurred.

conclusionsThis study met its primary endpoint of PFS, which is comparable to the results of the C-TASK FORCE study. The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC.

Indexed as

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDisease-Free SurvivalDrug CombinationsFluorouracilHumansJapanLeucovorinPyrrolidinesThymineTrifluridineBevacizumabDrug CombinationsFluorouracilLeucovorinPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationBevacizumabChemotherapyColorectal cancerNeutropeniaTAS-102

Identifiers

PMID33083913
OpenAlexW3093500799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.